• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

c-TACE和DEB-TACE高危患者术后感染的抗生素预防性使用:一项病例对照研究

Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.

作者信息

Li Baojian

机构信息

Department of Pharmacy, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, Shanxi, China.

出版信息

J Healthc Eng. 2022 Apr 11;2022:6203817. doi: 10.1155/2022/6203817. eCollection 2022.

DOI:10.1155/2022/6203817
PMID:35444783
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9015880/
Abstract

OBJECTIVES

According to recent reports, prophylactic use of antibiotics is not always required in conventional transarterial chemoembolization (c-TACE). However, clinical evidence of prophylactic antibiotics in drug-eluting beads transarterial chemoembolization (DEB-TACE) to prevent postsurgical infection is limited. This study is aimed to evaluate the correlation between the preoperative prophylactic application of antibiotics and postoperative infection in c-TACE or DEB-TACE, especially in a population with a high risk for postsurgical infection.

METHODS

In this retrospective study, TACE patients diagnosed with hepatic carcinoma (between January 2019 and May 2021) were examined. The case group was given 1.5 g cefuroxime sodium 0.5-1 hour before TACE, while there was no intervention in the control group. The outcomes analyzed were leukocyte count >9.5 × 10/L on the second day after the operation and the diagnosis of infection within one month after the operation. We applied univariate, multivariate logistic regression, trend analysis, and subgroup analysis to find potential risk factors and the necessity of prophylactic antibiotics.

RESULTS

Among 142 eligible cases, 72 received antibiotics while 70 were kept as control, 113 cases were treated with c-TACE, and 29 were treated with DEB-TACE. Multivariate analysis showed that the increase in white blood cell count after the operation was related to diabetes (OR 5.112, 95% CI 1.229-21.264,  = 0.025). The occurrence of postoperative infection was negatively correlated with preoperative albumin value (<25 g/L) (OR 153.118, 95% CI 1.631-14372.331,  = 0.030). Trend analysis showed that the risk of postoperative infection increased with a decrease in serum albumin level ( < 0.05). Subgroup analysis showed that there were no significant differences in the incidence of increased leukocyte count and postoperative infection between the prophylactic and nonprophylactic treatment groups, in the case of diabetes, preoperative albumin levels, and operation mode ( > 0.1).

CONCLUSIONS

Prophylactic antibiotic treatment before the c-TACE or DEB-TACE had no significant correlation with postoperative leukocyte increase and postoperative infection. Diabetes history and serum albumin levels were the prominent risk factors associated with an increase in postoperative leukocyte count and postoperative infection. Future large-scale studies and randomized-controlled trials are required to confirm and validate this association.

摘要

目的

根据最近的报告,传统经动脉化疗栓塞术(c-TACE)并不总是需要预防性使用抗生素。然而,药物洗脱微球经动脉化疗栓塞术(DEB-TACE)中预防性使用抗生素以预防术后感染的临床证据有限。本研究旨在评估c-TACE或DEB-TACE术前预防性应用抗生素与术后感染之间的相关性,尤其是在术后感染高风险人群中。

方法

在这项回顾性研究中,对2019年1月至2021年5月期间诊断为肝癌的TACE患者进行了检查。病例组在TACE术前0.5 - 1小时给予1.5g头孢呋辛钠,而对照组未进行干预。分析的结果包括术后第二天白细胞计数>9.5×10⁹/L以及术后1个月内的感染诊断。我们应用单因素、多因素逻辑回归、趋势分析和亚组分析来寻找潜在风险因素以及预防性使用抗生素的必要性。

结果

在142例符合条件的病例中,72例接受了抗生素治疗而70例作为对照,113例接受c-TACE治疗,29例接受DEB-TACE治疗。多因素分析表明,术后白细胞计数增加与糖尿病有关(OR 5.112,95%CI 1.229 - 21.264,P = 0.025)。术后感染的发生与术前白蛋白值(<25g/L)呈负相关(OR 153.118,95%CI 1.631 - 14372.331,P = 0.030)。趋势分析表明,术后感染风险随着血清白蛋白水平的降低而增加(P<0.05)。亚组分析表明,在糖尿病、术前白蛋白水平和手术方式方面,预防性治疗组与非预防性治疗组之间白细胞计数增加和术后感染的发生率无显著差异(P>0.1)。

结论

c-TACE或DEB-TACE术前预防性抗生素治疗与术后白细胞增加和术后感染无显著相关性。糖尿病史和血清白蛋白水平是与术后白细胞计数增加和术后感染相关的突出风险因素。未来需要大规模研究和随机对照试验来证实和验证这种关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47c/9015880/8270c289fccc/JHE2022-6203817.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47c/9015880/8270c289fccc/JHE2022-6203817.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a47c/9015880/8270c289fccc/JHE2022-6203817.001.jpg

相似文献

1
Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.c-TACE和DEB-TACE高危患者术后感染的抗生素预防性使用:一项病例对照研究
J Healthc Eng. 2022 Apr 11;2022:6203817. doi: 10.1155/2022/6203817. eCollection 2022.
2
Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula.载药微球动脉化疗栓塞与常规动脉化疗栓塞治疗伴有门腔分流的肝细胞癌患者的疗效和安全性。
Cancer Biol Ther. 2022 Dec 31;23(1):89-95. doi: 10.1080/15384047.2021.2020059.
3
Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.载药微球栓塞术治疗原发性肝癌的近期疗效及安全性
J Cancer Res Ther. 2021 Jul;17(3):733-739. doi: 10.4103/jcrt.JCRT_1848_20.
4
CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.载药微球与碘化油动脉化疗栓塞治疗肝细胞癌的短期疗效及安全性比较:一项短期疗效和安全性研究。
World J Surg Oncol. 2018 Mar 27;16(1):69. doi: 10.1186/s12957-018-1368-8.
5
Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.经动脉化疗栓塞治疗肝细胞癌后肝动脉损伤:一项回顾性对照研究中药物洗脱微球与传统化疗栓塞的比较
Acta Radiol. 2017 Feb;58(2):131-139. doi: 10.1177/0284185116648501. Epub 2016 Jul 12.
6
Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.在实际临床环境中肝细胞癌的碘油灌注与载药微球经动脉化疗栓塞术的比较
Scand J Gastroenterol. 2019 Jul;54(7):905-912. doi: 10.1080/00365521.2019.1632925. Epub 2019 Jul 9.
7
The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.药物洗脱微球(与常规相比)经动脉化疗栓塞治疗中晚期肝细胞癌对肝纤维化的影响。
Cancer Biol Ther. 2023 Dec 31;24(1):2166335. doi: 10.1080/15384047.2023.2166335.
8
Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.不可切除肝细胞癌患者经载药微球与传统经动脉化疗栓塞治疗后的影像学改变及临床并发症:多中心研究。
AJR Am J Roentgenol. 2021 Oct;217(4):933-943. doi: 10.2214/AJR.20.24708. Epub 2020 Nov 27.
9
Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.肝细胞癌经动脉化疗栓塞术后的肝脏和胆道损伤:载药微球与碘油乳剂的比较
Eur Radiol. 2017 Apr;27(4):1431-1439. doi: 10.1007/s00330-016-4488-y. Epub 2016 Jul 19.
10
Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma.多柔比星洗脱微球与常规经动脉化疗栓塞治疗肝细胞癌的比较。
J Gastroenterol Hepatol. 2014 May;29(5):920-5. doi: 10.1111/jgh.12439.

引用本文的文献

1
Retracted: Prophylactic Use of Antibiotics for Postsurgical Infection in c-TACE and DEB-TACE High-Risk Patients: A Case-Control Study.撤回:经动脉化疗栓塞术(c-TACE)和载药微球经动脉化疗栓塞术(DEB-TACE)高危患者术后感染预防性使用抗生素:一项病例对照研究。
J Healthc Eng. 2023 Sep 27;2023:9849480. doi: 10.1155/2023/9849480. eCollection 2023.
2
Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association.经动脉化疗栓塞治疗肝细胞癌:2023 年韩国肝癌协会基于专家共识的实用推荐。
Clin Mol Hepatol. 2023 Jul;29(3):521-541. doi: 10.3350/cmh.2023.0202. Epub 2023 Jul 1.
3

本文引用的文献

1
Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.载药微球化疗栓塞后转移性肝肿瘤患者发生肝脓肿。
Br J Radiol. 2022 Jan 1;95(1129):20211056. doi: 10.1259/bjr.20211056. Epub 2021 Nov 29.
2
Initial Experience of Drug-Eluting Bead-Transcatheter Arterial Chemoembolization After Lipiodol-Based Transcatheter Arterial Chemoembolization Failure for Patients with Advanced Hepatocellular Carcinoma.碘油栓塞化疗失败后应用载药微球经动脉化疗栓塞治疗晚期肝细胞癌患者的初步经验
Cancer Manag Res. 2021 Oct 19;13:7973-7980. doi: 10.2147/CMAR.S332571. eCollection 2021.
3
Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association.
肝细胞癌经动脉化疗栓塞术:韩国肝癌协会基于2023年专家共识的实用建议
J Liver Cancer. 2023 Sep;23(2):241-261. doi: 10.17998/jlc.2023.05.22. Epub 2023 Jul 14.
4
Transarterial Chemoembolization for Hepatocellular Carcinoma: 2023 Expert Consensus-Based Practical Recommendations of the Korean Liver Cancer Association.经动脉化疗栓塞术治疗肝细胞癌:韩国肝癌协会基于 2023 年专家共识的实用推荐建议。
Korean J Radiol. 2023 Jul;24(7):606-625. doi: 10.3348/kjr.2023.0385.
Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis.
经动脉化疗栓塞术治疗肝细胞癌后感染的危险因素:系统评价和荟萃分析方案。
Medicine (Baltimore). 2021 May 21;100(20):e25851. doi: 10.1097/MD.0000000000025851.
4
Association between prophylactic antibiotic use for transarterial chemoembolization and occurrence of liver abscess: a retrospective cohort study.预防性使用抗生素与经动脉化疗栓塞术后肝脓肿发生的关系:一项回顾性队列研究。
Clin Microbiol Infect. 2021 Oct;27(10):1514.e5-1514.e10. doi: 10.1016/j.cmi.2021.01.014. Epub 2021 Jan 16.
5
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).肝细胞癌诊疗指南(2019年版)
Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.
6
Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.载药微球与碘油经动脉化疗栓塞术治疗乏血供肝细胞癌的单中心回顾性研究
Cancer Manag Res. 2020 Jul 6;12:5461-5468. doi: 10.2147/CMAR.S255960. eCollection 2020.
7
Incorporation of biochemical factors for survival analysis of transarterial chemoembolization in patients with hepatocellular carcinoma: A retrospective cohort study.纳入生化因素用于肝细胞癌患者经动脉化疗栓塞生存分析:一项回顾性队列研究。
J Int Med Res. 2019 Oct;47(10):4862-4871. doi: 10.1177/0300060519866941. Epub 2019 Aug 26.
8
[Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma].[肝细胞癌经动脉化疗栓塞术中国临床实践指南]
Zhonghua Gan Zang Bing Za Zhi. 2019 Mar 20;27(3):172-181. doi: 10.3760/cma.j.issn.1007-3418.2019.03.003.
9
Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.经载药微球的经动脉化疗栓塞术治疗肝细胞癌的最新进展。
Korean J Radiol. 2019 Jan;20(1):34-49. doi: 10.3348/kjr.2018.0088. Epub 2018 Dec 27.
10
Retrospective Analysis of Chinese Patients with Hepatocellular Carcinoma (HCC) undergoing Transcatheter Arterial Chemoembolization (TACE) with or without Prophylactic Antibiotic Therapy.对接受或未接受预防性抗生素治疗的经导管动脉化疗栓塞术(TACE)的中国肝细胞癌(HCC)患者的回顾性分析。
J Coll Physicians Surg Pak. 2018 Dec;28(12):914-918. doi: 10.29271/jcpsp.2018.12.914.